Partial
Partially Misaligned
Patient Risk:
Moderate
Summary
Most core mechanism/indication statements and some adverse reaction descriptions align with the provided label excerpts, but several dosing, pregnancy labeling, and administration/clinical details conflict or are unsupported. Several non-label claims (marketing, cost, patents, preservative-free, meibomian gland dysfunction, etc.) cannot be supported by the supplied excerpts.
Category Scores
Accurate Statements
Miebo (perfluorohexyloctane ophthalmic solution) is an FDA-approved eye drop for treating dry eye disease in adults.
Section 1 INDICATIONS AND USAGE: indicated for treatment of the signs and symptoms of dry eye disease (DED). (Label excerpt provided does not specifically state “adults” but implies use in DED patients; adult-specific text not included in excerpts.)
Miebo targets the signs and symptoms of dry eye by reducing tear evaporation.
Section 12.1 MECHANISM OF ACTION: forms a monolayer at air-liquid interface which can be expected to reduce evaporation.
Miebo forms a protective layer on the eye's surface to prevent tear evaporation.
Section 12.1 MECHANISM OF ACTION: forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. (“protective layer” is consistent with forming a monolayer at the interface.)
Some patients report blurred vision lasting seconds to minutes after dosing.
Section 6.1 ADVERSE REACTIONS: most common ocular adverse reaction was blurred vision; blurred vision and conjunctival redness reported in 1-3%. (Label excerpt does not provide duration “seconds to minutes,” so only the presence of blurred vision is supported.)
Some patients report eye redness.
Section 6.1 ADVERSE REACTIONS: conjunctival redness reported in 1-3%.
Some patients report eye pain.
No label excerpt provided for “eye pain” as an adverse reaction.
Unsupported Statements
Miebo addresses meibomian gland dysfunction, a common cause of dry eye.
No label excerpt provided mentions meibomian gland dysfunction or MGD as an indication/target.
The recommended dosing is apply one drop in each eye twice daily.
Label excerpt states instill one drop four times daily (QID), not twice daily.
Miebo is marketed by Novartis through its acquisition of Bausch + Lomb.
No label excerpt provided includes marketing company or acquisition history.
The FDA approved Miebo in May 2023.
No label excerpt provided includes approval date.
Miebo approval was based on two phase 3 trials showing significant improvement in tear break-up time.
Label excerpt provided describes two randomized multicenter trials (GOBI and MOJAVE) with statistically significant reductions in tCFS and VAS dryness scores, but does not mention “phase 3” or “tear break-up time” specifically.
Some patients report blurred vision lasting seconds to minutes after dosing.
Label excerpt supports blurred vision as an adverse reaction but does not specify timing/duration after dosing.
Miebo is preservative-free.
No label excerpt provided states preservative-free.
Miebo pregnancy category is unknown.
Label excerpt instead states: “There are no adequate and well controlled studies with MIEBO in pregnant women.” It does not describe a “pregnancy category” being unknown.
Miebo physically stabilizes the tear film without steroids.
Label excerpt provides monolayer/evaporation reduction but does not state “without steroids” or discuss steroid absence.
Miebo avoids common preservatives that irritate sensitive eyes.
No label excerpt provided discusses preservatives or comparative irritation.
Costs about $700–$900 for a 30-day supply without insurance.
No label excerpt provided includes pricing.
No generics for Miebo have been approved yet.
No label excerpt provided includes generic approval status.
A key patent on Miebo's formulation (U.S. Patent 10,987,347) expires around 2038–2040.
No label excerpt provided includes patent numbers or expiration dates.
Contradictions
High
AI Statement
The recommended dosing is apply one drop in each eye twice daily.
Label Reference
Section 2.1 Recommended Dosage: “Instill one drop of MIEBO four times daily into affected eye(s).”
Important Omissions
Contact lens removal timing (remove prior to and for at least 30 minutes after administration).
Importance:
Moderate
Correct administration frequency (QID) and dosing into affected eye(s) rather than BID.
Importance:
High
Label-specified contraindication: history of hypersensitivity to perfluorohexyloctane.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A direct dosing contradiction (BID vs label QID) could lead to underdosing or incorrect use. Several other unsupported statements (e.g., preservative-free, steroid-free) and missing required precaution about contact lenses could affect safe administration.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Misaligned
Primary Issue
Incorrect dosing frequency (twice daily vs label four times daily) and multiple unsupported/non-label claims (company history, approval date, phase/trial endpoint phrasing, preservative-free, steroid absence, pricing/generics/patent details).
Suggested Improvement
Replace BID dosing with the label’s QID dosing (one drop four times daily into affected eye(s)), add the contact lens removal precaution (remove prior to and at least 30 minutes after), and restrict statements to label-supported content (indication, monolayer/evaporation reduction mechanism, and adverse reactions documented as blurred vision and conjunctival redness). Remove or qualify non-label claims not present in the provided label excerpts.